---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-055462"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2026-05-13T12:05:18+00:00"
generated_at: "2026-05-13T12:20:07.329669+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC

## Summary
- Cash and cash equivalents and investments of $177.4 million as of March 31, 2026, expected to fund operations into 2028.
- Net loss of $17.8 million ($0.31 per share) for Q1 2026, compared to $11.9 million loss in Q1 2025.
- Intends to submit BLA for TARA-002 in Lymphatic Malformations in second half of 2027 based on STARBORN-1 trial.
- Expects to complete enrollment of BCG-Unresponsive cohort in ADVANCED-2 trial and initiate ADVANCED-3 trial in BCG-Naïve patients in second half of 2026.
- Updated interim safety and durability data from STARBORN-1 to be presented at ISSVA World Congress in May 2026.

## SEC filing metadata
- accession: 0001213900-26-055462
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2026-05-13T12:05:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/0001213900-26-055462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea0288581-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-055462
- JSON: https://secwatch.observer/filing/0001213900-26-055462.json
- Plain text: https://secwatch.observer/filing/0001213900-26-055462.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $17.8 million, or $0.31 per share, EPS $0.31 per share.
  - Period: the first quarter ended March 31, 2026
  - Net income: $17.8 million, or $0.31 per share
  - EPS: $0.31 per share
  - Result: reported results
  source text: For the first quarter of 2026, Protara incurred a net loss of $17.8 million, or $0.31 per share, compared with a net loss of $11.9 million, or $0.29 per share, for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/0001213900-26-055462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.